As it preps Phase III kidney trial on its own, AM-Pharma raises €116M series C

As it preps Phase III kidney trial on its own, AM-Pharma raises €116M series C

Source: 
BioCentury
snippet: 

After Pfizer declined to exercise its option to acquire AM-Pharma, the Dutch biotech has turned to European venture investors for a €116 million ($131 million) series C round to fund a Phase III study of recAP to treat acute kidney injury candidate.